MOUNTAIN VIEW, Calif. , Nov. 30, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the Company will host a conference call and live audio webcast on Saturday,

MOUNTAIN VIEW, Calif. , Nov. 23, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, has participated in a fireside chat in

MOUNTAIN VIEW, Calif. , Nov. 09, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, will present at three upcoming investor

MOUNTAIN VIEW, Calif. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- - Initial D ata from Phase 1 T rial of IGM-2323 in R elapsed/ r efractory N on-Hodgkin’s L ymphoma   to be Presented at the 62nd American Society of Hematology Annual Meeting and Exposition in December - -   First-in-Human Clinical Trial of

- Abstract Shows Encouraging Safety and Cytokine Release Data, Preservation of T cell Function and Repeatable T cell Activation - MOUNTAIN VIEW, Calif. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing

MOUNTAIN VIEW, Calif. , Sept. 30, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating

- Multi-year, Multi-target Agreement Intended to Expedite Discovery of Novel IgM Antibodies - VANCOUVER, British Columbia and MOUNTAIN VIEW, Calif. , Sept. 24, 2020 (GLOBE NEWSWIRE) -- AbCellera and IGM Biosciences, Inc. (Nasdaq: IGMS), announced today that they have entered into a multi-year,

MOUNTAIN VIEW, Calif. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer , Chief Executive Officer, will present at four upcoming investor

­   - IND for IGM-8444 for treatment of patients with solid cancers cleared by FDA - - Kathy Miller , Ph.D., appointed Vice President, Antibody Discovery - - Phase I clinical trial of IGM-2323 continues - MOUNTAIN VIEW, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc.

MOUNTAIN VIEW, Calif. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 2020 Wedbush PacGrow